Despite how common GLP-1 use has become, there has been relatively little dermatology-focused research on their cutaneous side effects, with most of the existing literature limited to individual case reports. For the cross-sectional analysis, Fat and colleagues compared cutaneous adverse events reported in the FDA Adverse Event Reporting System (FAERS) for the GLP-1 receptor agonists semaglutide (Ozempic/ Wegovy, Novo Nordisk), liraglutide, exenatide and dulaglutide (Trulicity, Eli Lilly) with cutaneous adverse event reports for the dipeptidyl peptidase-4 (DPP-IV) inhibitors sitagliptin, saxagliptin, linagliptin and alogliptin
The GLP-1 Receptor Pathway Slows gastric emptying, helping you feel full longer after meals Signals the brain to reduce appetite and food intake through natural appetite suppression Supports better blood sugar control by enhancing insulin secretion when glucose levels are elevated Improves insulin resistance at the cellular level The GIP Receptor Pathway Works alongside GLP-1 to improve insulin sensitivity and glucose metabolism May enhance fat metabolism and energy utilization Contributes to improved glycemic control and HbA1c reduction Supports the bodys natural metabolic regulation Clinical Evidence & FDA Approval Tirzepatide received FDA approval for type 2 diabetes management (as Mounjaro) and obesity treatment (as Zepbound) based on robust clinical trial data
Who does the post say should not pursue this combination at all
Among the emerging areas of interest are therapies originally developed for metabolic disease that appear to influence multiple aging-related pathways
Before taking your first bath after C-section, always check with your healthcare provider
Individual tolerance varies, so monitoring your bodys response is essential, particularly if youre on semaglutide
